Awakn Life Sciences ( (TSE:AWKN) ) just unveiled an announcement.
Awakn Life Sciences Corp. announced that its shareholders have overwhelmingly approved a statutory plan of arrangement with Solvonis Therapeutics plc, allowing Solvonis to acquire all outstanding common shares, restricted share units, and deferred share units of Awakn. This arrangement, pending final approval from the Supreme Court of British Columbia, is expected to close before May 31, 2025, and signifies a strategic move for Awakn in aligning with Solvonis, a company focused on mental health and substance use disorder therapeutics.
More about Awakn Life Sciences
Awakn Life Sciences Corp. is a clinical-stage biotechnology company focused on developing therapeutics for addiction, with a near-term focus on Alcohol Use Disorder. The company aims to commercialize its R&D pipeline across multiple channels to provide breakthrough therapeutics for addiction sufferers.
YTD Price Performance: 8.33%
Technical Sentiment Signal: Buy
Current Market Cap: $2.86M
Learn more about AWKN stock on TipRanks’ Stock Analysis page.